LEADER 00880cam0 2200277 450 001 000003308 005 20090121133200.0 010 $a0-19-924868-0 100 $a20011130d2001----km-y0itay50------ba 101 0 $aeng 102 $aGB 105 $aa-------001yy 200 1 $aIncentives and political economy$fJean-Jacques Laffont 210 $aOxford$cOxford university press$d2001 215 $aXII, 257 p.$cgraf.$d22 cm 225 2 $aClarendon lectures in economics 410 0$12001$aClarendon lectures in economics 451 0$1001000021893 500 10$aIncentives and political economy$946830 610 1 $aEconomia dell'informazione 700 1$aLaffont,$bJean-Jacques$0437953 801 0$aIT$bUNIPARTHENOPE$gRICA$2UNIMARC 912 $a000003308 951 $a026/54$b9574$cNAVA2$d20011130 996 $aIncentives and political economy$946830 997 $aUNIPARTHENOPE LEADER 01610nam 2200421Ka 450 001 9910696402703321 005 20080404114000.0 035 $a(CKB)5470000002378819 035 $a(OCoLC)219652066 035 $a(EXLCZ)995470000002378819 100 $a20080404d2008 ua 0 101 0 $aeng 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aFacilitating access to Medicare Part D drug claims data$b[electronic resource] /$fElizabeth Hargrave ; Jack Hoadley 210 1$aWashington, DC :$cMedPAC,$d2008. 215 $aii unnumbered pages, v, 24 pages $cdigital, PDF file 225 1 $a[MedPAC contract research series] ;$v08-2 300 $aTitle from title screen (viewed Apr. 4, 2008). 300 $a"A study conducted by staff from Georgetown University and from NORC at the University of Chicago for the Medicare Payment Advisory Commission." 300 $a"March 2008." 320 $aIncludes bibliographical references. 606 $aMedicare$xEvaluation 606 $aDrug utilization$zUnited States$xEvaluation 606 $aMedical records$xAccess control$zUnited States 615 0$aMedicare$xEvaluation. 615 0$aDrug utilization$xEvaluation. 615 0$aMedical records$xAccess control 700 $aHargrave$b Elizabeth$01390567 701 $aHoadley$b Jack$01388689 712 02$aMedicare Payment Advisory Commission (U.S.) 801 0$bGPO 801 1$bGPO 906 $aBOOK 912 $a9910696402703321 996 $aFacilitating access to Medicare Part D drug claims data$93443404 997 $aUNINA